Cargando…

Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant

Fast-spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) energize the COVID-19 pandemic. The B.1.351 variant carrying the escape mutation E484K in the receptor binding domain is of particular concern due to reduced immunological protection following vaccination. Protec...

Descripción completa

Detalles Bibliográficos
Autores principales: Knabl, Ludwig, Lee, Hye Kyung, Wieser, Manuel, Mur, Anna, Zabernigg, August, Rauch, Simon, Bock, Matthias, Schumacher, Jana, Kaiser, Norbert, Furth, Priscilla A., Hennighausen, Lothar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132253/
https://www.ncbi.nlm.nih.gov/pubmed/34013280
http://dx.doi.org/10.1101/2021.05.11.21256862
_version_ 1783694880036356096
author Knabl, Ludwig
Lee, Hye Kyung
Wieser, Manuel
Mur, Anna
Zabernigg, August
Knabl, Ludwig
Rauch, Simon
Bock, Matthias
Schumacher, Jana
Kaiser, Norbert
Furth, Priscilla A.
Hennighausen, Lothar
author_facet Knabl, Ludwig
Lee, Hye Kyung
Wieser, Manuel
Mur, Anna
Zabernigg, August
Knabl, Ludwig
Rauch, Simon
Bock, Matthias
Schumacher, Jana
Kaiser, Norbert
Furth, Priscilla A.
Hennighausen, Lothar
author_sort Knabl, Ludwig
collection PubMed
description Fast-spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) energize the COVID-19 pandemic. The B.1.351 variant carrying the escape mutation E484K in the receptor binding domain is of particular concern due to reduced immunological protection following vaccination. Protection can manifest as early as 10 days following immunization with full protection two weeks following the second dose, but the course is not well-characterized for variants. Here, we investigated the immune transcriptome of six elderly individuals (average age 82 yr.) from an old people’s home, who contracted B.1.351, with four having received the first dose of BNT162b eight to 11 days prior to the onset of COVID-19 symptoms. The patients were hospitalized and received dexamethasone treatment. Immune transcriptomes were established from PBMCs approximately 10 and 35 days after the onset of COVID-19 symptomology. RNA-seq revealed a more intensive immune response in vaccinated patients as compared to unvaccinated ones. Specifically, transcription factors linked to the JAK/STAT pathway, interferon stimulated genes, and genes associated with innate antiviral immunity and COVID-19-SARS-CoV-2 infection were highly enriched in vaccinated patients. This rendered the transcriptomes of the older vaccinated group significantly different than older unvaccinated individuals infected at the same institution and more similar to the immune response of younger unvaccinated individuals (age range 48–62) following B.1.351 infection. All individuals in this study whether vaccinated or not were hospitalized due to B.1.351 infection and one vaccinated patient died illustrating that although an enhanced immune response was documented infection it was insufficient to protect from disease. This highlights the need for maintaining physical distancing and prevention measures throughout the time course of vaccination in older adults.
format Online
Article
Text
id pubmed-8132253
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-81322532021-05-20 Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant Knabl, Ludwig Lee, Hye Kyung Wieser, Manuel Mur, Anna Zabernigg, August Knabl, Ludwig Rauch, Simon Bock, Matthias Schumacher, Jana Kaiser, Norbert Furth, Priscilla A. Hennighausen, Lothar medRxiv Article Fast-spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) energize the COVID-19 pandemic. The B.1.351 variant carrying the escape mutation E484K in the receptor binding domain is of particular concern due to reduced immunological protection following vaccination. Protection can manifest as early as 10 days following immunization with full protection two weeks following the second dose, but the course is not well-characterized for variants. Here, we investigated the immune transcriptome of six elderly individuals (average age 82 yr.) from an old people’s home, who contracted B.1.351, with four having received the first dose of BNT162b eight to 11 days prior to the onset of COVID-19 symptoms. The patients were hospitalized and received dexamethasone treatment. Immune transcriptomes were established from PBMCs approximately 10 and 35 days after the onset of COVID-19 symptomology. RNA-seq revealed a more intensive immune response in vaccinated patients as compared to unvaccinated ones. Specifically, transcription factors linked to the JAK/STAT pathway, interferon stimulated genes, and genes associated with innate antiviral immunity and COVID-19-SARS-CoV-2 infection were highly enriched in vaccinated patients. This rendered the transcriptomes of the older vaccinated group significantly different than older unvaccinated individuals infected at the same institution and more similar to the immune response of younger unvaccinated individuals (age range 48–62) following B.1.351 infection. All individuals in this study whether vaccinated or not were hospitalized due to B.1.351 infection and one vaccinated patient died illustrating that although an enhanced immune response was documented infection it was insufficient to protect from disease. This highlights the need for maintaining physical distancing and prevention measures throughout the time course of vaccination in older adults. Cold Spring Harbor Laboratory 2021-05-14 /pmc/articles/PMC8132253/ /pubmed/34013280 http://dx.doi.org/10.1101/2021.05.11.21256862 Text en https://creativecommons.org/publicdomain/zero/1.0/This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license (https://creativecommons.org/publicdomain/zero/1.0/) .
spellingShingle Article
Knabl, Ludwig
Lee, Hye Kyung
Wieser, Manuel
Mur, Anna
Zabernigg, August
Knabl, Ludwig
Rauch, Simon
Bock, Matthias
Schumacher, Jana
Kaiser, Norbert
Furth, Priscilla A.
Hennighausen, Lothar
Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
title Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
title_full Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
title_fullStr Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
title_full_unstemmed Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
title_short Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
title_sort impact of bnt162b first vaccination on the immune transcriptome of elderly patients infected with the b.1.351 sars-cov-2 variant
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132253/
https://www.ncbi.nlm.nih.gov/pubmed/34013280
http://dx.doi.org/10.1101/2021.05.11.21256862
work_keys_str_mv AT knablludwig impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT leehyekyung impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT wiesermanuel impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT muranna impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT zaberniggaugust impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT knablludwig impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT rauchsimon impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT bockmatthias impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT schumacherjana impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT kaisernorbert impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT furthpriscillaa impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant
AT hennighausenlothar impactofbnt162bfirstvaccinationontheimmunetranscriptomeofelderlypatientsinfectedwiththeb1351sarscov2variant